Bioactivity | Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4]. |
Invitro | Azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling[5]. Cell Proliferation Assay[5] Cell Line: |
In Vivo | Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model[2].Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model[2].Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model[2]. Animal Model: |
Name | Azelastine |
CAS | 58581-89-8 |
Formula | C22H24ClN3O |
Molar Mass | 381.90 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Craig La Force. Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloridel. Expert Rev Clin Immunol. 2005 Jul;1(2):191-201. [2]. Mohamed M Elseweidy, et al. Azelastine a potent antihistamine agent, as hypolipidemic and modulator for aortic calcification in diabetic hyperlipidemic rats model. Arch Physiol Biochem. 2020 Jul 2;1-8. [3]. Carlos D. Zappia, et al. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model. Pharmacol Res Perspect. 2019 Dec; 7(6): e00531. [4]. Li Yang, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin. 2020 Oct 28 : 1-7. [5]. Shao-Cheng Liu, et al. Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. Eur Arch Otorhinolaryngol. 2017 Feb;274(2):845-853. |